Showing results (661-670 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|April 3, 2025
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS databaseMeina Lv, Jianhui Chen, Bin Zheng, et al.Expert Opinion on Drug Safety|April 19, 2025
Management of refractory checkpoint inhibitor-induced colitisAnas Zaher, Maria Julia Moura Nascimento Santos, Hassan Elsaygh, et al.Expert Opinion on Drug Safety|April 15, 2025
Adverse events of concomitant use of immune checkpoint inhibitors and metformin or statin: an observational, retrospective disproportionality analysisWenjie Li, Wei WangExpert Opinion on Drug Safety|June 13, 2024
Anti-seizure medications-associated bladder and urethral symptoms: a pharmacovigilance analysis based on the FAERS databaseYanyan Li, Zhanshen Wu, Yang Zhao, et al.Expert Opinion on Drug Safety|June 28, 2024
The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infantsAshley Wang, Alexandra Tsivitis, Sijia Ma, et al.Expert Opinion on Drug Safety|June 7, 2024
An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumorsAayushi Sood, Malak Munir, Omar Syed, et al.Expert Opinion on Drug Safety|May 23, 2024
Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancerMan Xu, Zhuo Ma, Xin Feng, et al.Expert Opinion on Drug Safety|May 16, 2024
Risk of drug-induced delirium in older patients- a pharmacovigilance study of FDA adverse event reporting system databaseBoying Jia, Shuang Zhou, Jiayu Li, et al.Expert Opinion on Drug Safety|June 20, 2024
Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemicJean-Luc Cracowski, Mathieu Molimard, Vincent Richard, et al.Expert Opinion on Drug Safety|May 28, 2024
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)Roger S McIntyre, Sabrina Wong, Angela T H Kwan, et al.Pageof 282